Toth Financial Advisory Corp Lowers stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : Toth Financial Advisory Corp reduced its stake in Johnson & Johnson by 2.51% during the most recent quarter end. The investment management company now holds a total of 55,256 shares of Johnson & Johnson which is valued at $6,534,575 after selling 1,423 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on Oct 13, 2016.Johnson & Johnson makes up approximately 1.97% of Toth Financial Advisory Corp’s portfolio.

Other Hedge Funds, Including , At Bancorp reduced its stake in JNJ by selling 327 shares or 2.02% in the most recent quarter. The Hedge Fund company now holds 15,826 shares of JNJ which is valued at $1,871,583. Johnson & Johnson makes up approx 0.26% of At Bancorp’s portfolio.E&g Advisors Lp reduced its stake in JNJ by selling 180 shares or 2.46% in the most recent quarter. The Hedge Fund company now holds 7,150 shares of JNJ which is valued at $856,570. Johnson & Johnson makes up approx 0.50% of E&g Advisors Lp’s portfolio.Gofen Glossberg Il reduced its stake in JNJ by selling 3,494 shares or 0.61% in the most recent quarter. The Hedge Fund company now holds 569,464 shares of JNJ which is valued at $68,221,787. Johnson & Johnson makes up approx 2.84% of Gofen Glossberg Il’s portfolio.Central Bank Trust Co boosted its stake in JNJ in the latest quarter, The investment management firm added 114 additional shares and now holds a total of 16,842 shares of Johnson & Johnson which is valued at $2,008,240. Johnson & Johnson makes up approx 0.57% of Central Bank Trust Co’s portfolio.Cullinan Associates Inc reduced its stake in JNJ by selling 5,237 shares or 3.33% in the most recent quarter. The Hedge Fund company now holds 152,070 shares of JNJ which is valued at $18,123,703. Johnson & Johnson makes up approx 1.56% of Cullinan Associates Inc’s portfolio.

Johnson & Johnson closed down -2.16 points or -1.80% at $117.64 with 63,94,159 shares getting traded on Tuesday. Post opening the session at $119.41, the shares hit an intraday low of $117.06 and an intraday high of $119.63 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.

Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.